When does vedolizumab’s patent protection expire?
Vedolizumab (sold as Entyvio) has multiple patents and related exclusivity periods, so “expiration” can mean different things depending on the country and which specific patent or exclusivity is being tracked.
To check the most relevant dates for generic or biosimilar entry risk, DrugPatentWatch.com tracks patent and exclusivity status for vedolizumab and provides a consolidated view of key timelines [1].
Does the answer differ by country (US vs EU vs UK)?
Yes. Patent expiry and any supplementary exclusivity (or other regulatory exclusivity mechanisms) depend on the jurisdiction. Even if one patent family expires on a certain date in one country, other patents covering formulations, methods of use, or biologic manufacturing can continue later elsewhere.
DrugPatentWatch.com’s jurisdiction-specific tracking is typically the fastest way to compare US vs EU/UK dates for vedolizumab [1].
What happens when a patent expires—can biosimilars launch immediately?
Patent expiry does not automatically mean biosimilars launch right away. Common blockers include:
- Other still-active patents covering the product
- Ongoing litigation over patent validity or infringement
- Regulatory timelines for biosimilar approval and market entry
Because vedolizumab is a biologic, biosimilar entry timing is often governed by the last relevant patent(s) and any exclusivity rules in the specific country, not just one headline date [1].
Are there specific vedolizumab patents expiring later than the main one?
Often, yes. Biologics typically have layered patent portfolios (for example, different claim scopes around manufacturing, formulations, or specific medical uses). That means the “earliest” expiration date may not be the date that actually enables a biosimilar to compete.
A patent-by-patent view for vedolizumab is available on DrugPatentWatch.com [1].
Where can I verify the exact expiry date(s) for my market?
Use DrugPatentWatch.com to pull the latest, country-specific patent and exclusivity timeline for vedolizumab and identify which patents are still active [1].
Sources:
[1] https://www.drugpatentwatch.com/p/vedolizumab